These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study. Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants. Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028). Ishihara Y; Kuroki H; Hidaka H; Iwai K; Wan K; Shirakawa M; Sawata M Hum Vaccin Immunother; 2023 Dec; 19(1):2180973. PubMed ID: 36882898 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160 [TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Benfield T; Rämet M; Valentini P; Seppä I; Dagan R; Richmond P; Mercer S; Churchill C; Lupinacci R; McFetridge R; Park J; Wittke F; Banniettis N; Musey L; Bickham K; Kaminski J Vaccine; 2023 Apr; 41(15):2456-2465. PubMed ID: 36841723 [TBL] [Abstract][Full Text] [Related]
16. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age. Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976 [TBL] [Abstract][Full Text] [Related]
17. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J; Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892 [TBL] [Abstract][Full Text] [Related]
18. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327 [TBL] [Abstract][Full Text] [Related]
19. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Bili A; Dobson S; Quinones J; Phongsamart W; Oberdorfer P; Kosalaraksa P; Dagan R; Richmond P; Wilck M; Vallejos W; Nunn C; McFetridge R; Tamms G; Fu R; Lupinacci R; Musey L; Banniettis N; Bickham K; Vaccine; 2023 Jan; 41(3):657-665. PubMed ID: 36522265 [TBL] [Abstract][Full Text] [Related]
20. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]